Isabella Hornick

The FDA has authorized marketing of a risk modification claim on 20 Zyn nicotine pouch products that were authorized for sale in the U.S. last year.According to an FDA press release, marketing of these products can now include the modified risk claim that “using Zyn instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic

In adults with prior preventive migraine treatment failures, an investigational monoclonal antibody led to larger decreases in monthly migraine days vs. placebo, according to a poster presented at a recent conference.Bocunebart (Lu AG09222, Lundbeck) is a monoclonal antibody that targets the pituitary adenylate cyclase-activating polypeptide (PACAP) ligand, according to the presentation at the

Amateur soccer players who headed the ball in a match vs. those who did not had significantly higher increases in S100B calcium-binding protein immediately after the match, according to results published in JAMA Neurology. “Soccer heading was associated with acute increases in blood biomarkers for neural damage, including dose-response relationships,” Marloes I. Hoppen, MSc, PhD candidate in

Through stories shared by real people and a fictional narrative based on a common traumatic situation, the docudrama, “May Contain: My Life,” exposes people to what life with food allergies looks and feels like.In addition to individuals with food allergies and their families, this film includes Ruchi S. Gupta, MD, MPH, director of the Center for Food Allergy & Asthma Research and

ORLANDO — Among adults with mild to severe obstructive sleep apnea, those receiving AD109, an oral combination drug, vs. placebo achieved lower disease severity at 26 weeks, according to pooled phase 3 trial results presented here.AD109 (Apnimed) is made up of 2.5 mg aroxybutynin, a novel antimuscarinic, and 75 mg atomoxetine, a selective norepinephrine reuptake inhibitor, according to a

ORLANDO — Nearly 70% of patients with positional obstructive sleep apnea who discontinued positional therapy after achieving disease control still had control at 1 year, according to findings presented here.“These findings support a more personalized approach to OSA,” Irene Cano-Pumarega, MD, PhD, pneumonologist and head of the sleep unit at Ramn y Cajal Hospital in Madrid, told

A pilot study, supported by the Food Allergy Fund, plans to assess metformin as a treatment in patients with peanut allergy.Notably, this effort is part of the Food Allergy Fund’s drug repurposing program.

ORLANDO — At this year’s American Thoracic Society International Conference, Joy Nkiru Eze, MBBS, MPH, MSc, MPhil, received the Philip Hopewell Prize for Global Respiratory Health Research. “Sometimes I lack the words to express how I feel, but I feel on top of the world,” Eze, professor of pediatrics and consultant pediatric pulmonologist at the University of Nigeria and

ORLANDO — Patients with COPD had larger improvements in FEV1 with a nebulized fixed-dose combination of indacaterol and glycopyrrolate vs. placebo, according to results presented at the American Thoracic Society International Conference.The long-acting beta-agonist indacaterol and the long-acting muscarinic antagonist glycopyrrolate make up AERO-007 (AeroRx Therapeutics), according to the

ORLANDO — Following hospitalization for an exacerbation of interstitial lung disease related to systemic autoimmune rheumatic disease, more Black and Hispanic vs. white patients died at 1 year, according to data presented here.Further, this study presented at the American Thoracic Society International Conference found that a smaller proportion of Black vs. white patients received a lung